Theravance Biopharma (FRA:0TB) E10: €-1.57 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:0TB Theravance Biopharma Inc FRA:0TB
71 GF Score
Price €14.50
GF Value €15.17
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Theravance Biopharma E10?

Theravance Biopharma FRA:0TB 71 E10 is €-1.57 as of Jun. 2026. GuruFocus rates FRA:0TB with a GF Score™ of 71/100 and a GF Value™ of €15.17 (Fairly Valued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Theravance Biopharma's adjusted earnings per share data for the three months ended in Jun. 2026 was €-0.095. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-1.57 for the trailing ten years ended in Jun. 2026.

During the past 3 years, the average E10 Growth Rate was 20.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Theravance Biopharma was 20.70% per year. The lowest was 20.70% per year. And the median was 20.70% per year.

As of today (2026-09-14), Theravance Biopharma's current stock price is €14.50. Theravance Biopharma's E10 for the quarter that ended in Jun. 2026 was €-1.57. Theravance Biopharma's Shiller PE Ratio of today is .


Theravance Biopharma  (FRA:0TB) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Theravance Biopharma E10 Related Terms


Theravance Biopharma E10 Historical Data

* Premium members only.

The historical data trend for Theravance Biopharma's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theravance Biopharma E10 Chart

Theravance Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -3.75 -3.30 -2.79 -1.70

Theravance Biopharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.19 -1.93 -1.70 -1.56 -1.57

FRA:0TB vs ACRS, SGP, ATTO: E10 Comparison

For the Biotechnology subindustry, Theravance Biopharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theravance Biopharma Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theravance Biopharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Theravance Biopharma's Shiller PE Ratio falls into.


FRA:0TB
71GF Score
Theravance Biopharma Inc FRA:0TB
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Theravance Biopharma E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Theravance Biopharma's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.095/333.9520*333.9520
=-0.095

Current CPI (Jun. 2026) = 333.9520.

Theravance Biopharma Quarterly Data

per share eps CPI Adj_EPS
201609 -0.650 241.428 -0.899
201612 -1.289 241.432 -1.783
201703 -1.187 243.801 -1.626
201706 -1.130 244.955 -1.541
201709 -1.066 246.819 -1.442
201712 -1.386 246.524 -1.878
201803 -0.989 249.554 -1.323
201806 -0.651 251.989 -0.863
201809 -0.943 252.439 -1.247
201812 -0.809 251.233 -1.075
201903 -1.168 254.202 -1.534
201906 -0.637 256.143 -0.831
201909 -0.953 256.759 -1.240
201912 -1.053 256.974 -1.368
202003 -1.267 258.115 -1.639
202006 -0.888 257.797 -1.150
202009 -0.985 260.280 -1.264
202012 -0.756 260.474 -0.969
202103 -1.042 264.877 -1.314
202106 -0.664 271.696 -0.816
202109 -0.408 274.310 -0.497
202112 -0.381 278.802 -0.456
202203 -0.309 287.504 -0.359
202206 -0.104 296.311 -0.117
202209 12.261 296.808 13.795
202212 -0.142 296.797 -0.160
202303 -0.327 301.836 -0.362
202306 -0.258 305.109 -0.282
202309 -0.159 307.789 -0.173
202312 -0.156 306.746 -0.170
202403 -0.221 312.332 -0.236
202406 -0.316 314.175 -0.336
202409 -0.234 315.301 -0.248
202412 -0.296 315.605 -0.313
202503 -0.250 319.799 -0.261
202506 0.936 322.561 0.969
202509 0.060 324.800 0.062
202512 0.982 324.054 1.012
202603 -0.086 330.213 -0.087
202606 -0.095 333.952 -0.095

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-1.57 mean?
Theravance Biopharma (FRA:0TB) has a E10 of €-1.57 as of Jun. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Theravance Biopharma and its competitors.
Is Theravance Biopharma's E10 too high?
Theravance Biopharma's current E10 is €-1.57. Overall, Theravance Biopharma has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Theravance Biopharma's E10 compare to ACRS and SGP?
Theravance Biopharma's E10 of €-1.57 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Theravance Biopharma and its competitors. Theravance Biopharma's current E10 is €-1.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theravance Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Theravance Biopharma (FRA:0TB) is currently considered Fairly Valued. The stock's GF Value™ is €15.17, compared to a current price of €14.50 — trading 4.4% below its estimated fair value. The current E10 is €-1.57. Theravance Biopharma's overall GF Score™ is 71/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Theravance Biopharma (FRA:0TB), the current E10 is €-1.57 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Theravance Biopharma (FRA:0TB) Overvalued in 2026?

Based on GuruFocus' analysis, Theravance Biopharma stock appears to be undervalued. The current stock price of €14.50 is trading 4.4% below its estimated GF Value™ of €15.17. GuruFocus considers Theravance Biopharma to be Fairly Valued.

Key valuation signals for FRA:0TB:

  • E10: €-1.57
  • GF Value™: €15.17 vs. price of €14.50 (4.4% below fair value)
  • GF Score™: 71/100 with 2 warning signs

No single metric tells the full story. See the FRA:0TB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Theravance Biopharma Business Description

Other Exchanges TBPH:USA
Address C/O Theravance Biopharma US, LLC, 901 Gateway Boulevard, South San Francisco, CA, USA, 94080
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
71GF Score

Get the complete analysis for FRA:0TB

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€14.50
Price
€15.17
GF Value